Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Propagermanium crossover study in diabetic kidney disease
ACTRN12618000982213Phase 2Completed
- Sponsor
- Dimerix
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of repagermanium in diabetic glomerulosclerosis (2 arms), sponsored by Dimerix. Primary endpoint: Change in albumin/creatinine ratio. Started Nov 2018; status: completed.
02
Drugs
repagermanium
03
Conditions
diabetic glomerulosclerosis
Beyond the preview
Go deeper on ACTRN12618000982213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618000982213.